Skip to main content

Table 1 Comparative in vitro activity of eravacycline against selected Gram-positive clinical isolates

From: Eravacycline: A Review in Complicated Intra-Abdominal Infections

Pathogen Total no. of isolates MIC90 (μg/mL; range across studies) [% susceptible; CLSI or FDA/EUCAST]
ERV [NA] TGC TZP VAN
Aerobes
Enterococcus spp. [20] 406 0.06 1 [NR]   
E. faecalis [16, 24, 25] 1605 0.06–0.12 0.25 [98.1–99.5/NR] 4 [NA/NR] 2 [NR]
E. faecalis (VR) [18, 24] 108 0.12 0.25 [NR]   > 32 to > 64 [NR]
E. faecalis (VS) [18] 121 0.12 0.25[98.1/NR]   2 [92.5/NR]
E. faecium [16, 24, 25] 1149 0.06 0.12–0.25 [93.2/NR] >32 [NA/NR] >32 [26.8/NR]
E. faecium (VR) [18, 24] 379 0.06 0.12–0.25 [NR]   > 32 to > 64 [NR]
E. faecium (VS) [18] 84 0.12 0.12 [NR]   1 [NR]
Staphylococcus aureus [20, 24] 2024 0.12 0.25 [NR]   1 [NR]
MRSA [16, 18, 20, 21, 24, 25] 2247 0.06–0.12 0.25–1 [97.7–98.4/NR] 128 [NA] 1 [100/NR]
MSSA [16, 18, 21, 25] 2006 0.06–0.25 0.25 [99.6–99.9/NR] ≤ 1 [NA] 1 [100/NR]
Streptococcus anginosus [18] 47 0.03 0.06 [NR]   1 [NR]
Streptococcus intermedius [18] 31 0.06 0.12 [NR]   0.5 [NR]
Streptococcus mitis [18] 62 0.12 0.12 [NR]   0.5 [NR]
Anaerobes
Clostridium perfringens [15] 15 1 2 [100/NA] 1 [100/100] 32 [NA/80]
  1. Pathogens against which eravacycline has demonstrated efficacy in clinical trials [11, 13]. Studies involving >  500 clinical isolates collected in Canada (2014–2015 [16]), EU (2015 [21]), USA (2012–2015 [15]; 2013–2016 [25]; year(s) not stated [18]) or globally (2013–2015 [24]; year(s) not stated [20]); not all studies evaluated all drugs or reported susceptibility. Abstract presentations [20, 21, 24, 25]
  2. CLSI Clinical and Laboratory Standards Institute, ERV eravacycline, EUCAST European Committee on Antimicrobial Susceptibility Testing, MIC90 minimum inhibitory concentration required to inhibit 90% of isolates, MRSA methicillin-resistant S. aureus, MSSA methicillin-sensitive S. aureus, NA not applicable/no breakpoint, NR not reported, TGC tigecycline, TZP piperacillin/tazobactam, VAN vancomycin, VR VAN-resistant, VS VAN-sensitive
Back to article page